Kenvue (NYSE:KVUE) Stock Price Up 4.7% – Should You Buy?

Shares of Kenvue Inc. (NYSE:KVUE) were up 4.7% during mid-day trading on Friday . The company traded as high as $17.62 and last traded at $17.6650. Approximately 14,250,222 shares traded hands during mid-day trading, a decline of 56% from the average daily volume of 32,055,883 shares. The stock had previously closed at $16.88.

Analyst Ratings Changes

A number of equities analysts recently issued reports on KVUE shares. Citigroup decreased their price objective on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Wednesday, April 15th. Argus raised Kenvue to a “hold” rating in a report on Friday, March 6th. Weiss Ratings lowered Kenvue from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, May 29th. Canaccord Genuity Group increased their price objective on Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a report on Wednesday, February 18th. Finally, Zacks Research raised Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $19.33.

Kenvue Trading Up 4.9%

The business has a 50 day simple moving average of $17.37 and a 200-day simple moving average of $17.47. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.70 and a current ratio of 0.98. The stock has a market capitalization of $34.01 billion, a P/E ratio of 20.84, a price-to-earnings-growth ratio of 1.28 and a beta of 0.54.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $3.91 billion during the quarter, compared to analyst estimates of $3.84 billion. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The firm’s quarterly revenue was up 4.5% on a year-over-year basis. During the same period last year, the company posted $0.24 EPS. On average, analysts predict that Kenvue Inc. will post 1.16 EPS for the current year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th were paid a dividend of $0.2075 per share. This represents a $0.83 dividend on an annualized basis and a yield of 4.7%. The ex-dividend date of this dividend was Wednesday, May 13th. Kenvue’s dividend payout ratio (DPR) is presently 97.65%.

Insider Transactions at Kenvue

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the stock in a transaction on Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.59% of the company’s stock.

Institutional Investors Weigh In On Kenvue

Large investors have recently modified their holdings of the stock. Cornerstone Planning Group LLC boosted its stake in shares of Kenvue by 705.2% during the 3rd quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after acquiring an additional 1,361 shares in the last quarter. Physician Wealth Advisors Inc. boosted its stake in shares of Kenvue by 67.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after acquiring an additional 618 shares in the last quarter. Elyxium Wealth LLC bought a new stake in shares of Kenvue during the 4th quarter worth $26,000. MV Capital Management Inc. bought a new stake in shares of Kenvue during the 4th quarter worth $28,000. Finally, Reflection Asset Management bought a new stake in shares of Kenvue during the 4th quarter worth $32,000. 97.64% of the stock is owned by institutional investors.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over?the?counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.